DEAFinal Rule
Schedules of Controlled Substances: Extension of Temporary Placement of CUMYL-PEGACLONE in Schedule I
HealthcareOther
Ad Space (leaderboard)
Summary
The Drug Enforcement Administration (DEA) is extending its temporary ban on CUMYL-PEGACLONE, a synthetic drug similar to K2 or spice, by keeping it classified as an illegal substance. This means the drug remains prohibited and people cannot legally make, sell, or possess it.
Key Points
- 1CUMYL-PEGACLONE, a synthetic cannabinoid drug, remains illegal under federal law as a Schedule I controlled substance
- 2This is a temporary extension of an earlier ban, meaning the DEA is continuing its restriction rather than allowing the drug to become legal
- 3People caught making, selling, or possessing this drug face federal criminal penalties including fines and imprisonment
- 4The DEA extended this ban because the drug poses public health and safety risks similar to other banned synthetic drugs
- 5This regulation affects drug manufacturers, sellers, and users, as well as law enforcement agencies enforcing drug laws
Impact Assessment
If you are a manufacturer or seller of synthetic cannabinoids, this means you cannot legally produce, distribute, or sell CUMYL-PEGACLONE, and violations carry federal criminal penalties.
Impact Level
Routine
Geographic Scope
National
Compliance Cost
Minimal
Who is Affected
ManufacturersImporters/ExportersConsumers
Key Dates
Published
December 11, 2025
Regulatory Connections
Authorized By
Amends CFR Sections
21 CFR Part 1308
Other Documents in This Rulemaking (DEA-2025-0852)
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.
The Digest Network
Ad Space (rectangle)